semaglutide cardiovascular trial and Outcomes in Obesity without Diabetes 6 semaglutide Cardiovascular risk reduction

Supportive adjustments can make a meaningful difference

Update the plan as rules change

The trial shows that tirzepatide increases glomerular filtration rate (eGFR) when used for a longer time

Tirzepatide HypoSpray therapy may be considered for eligible adults who want provider-guided metabolic support and are interested in discussing a needle-free transdermal spray format

More specifically, tirzepatide is an agonist of both the glucose-dependent insulinotropic polypeptide (GIP) and the glucagon-like peptide-1 (GLP1) receptors

Long-term tirzepatide use and urinary health outlook As tirzepatide moves from a relatively new medication to an established long-term treatment option, understanding its effects on urinary health over extended periods becomes increasingly relevant